Drug Trial Radar · NCT06101823
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Nov 21, 2023
Primary completion
Sep 3, 2024
Study completion Aug 18, 2025
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Conditions
- Atopic Dermatitis
Interventions
OpSCFBiological
Administered SC.
PlaceboBiological
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16Time frame: Baseline, Week 16
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center
Birmingham, Alabama
First OC Dermatology Research
Fountain Valley, California
Axon Clinical Research
Inglewood, California
University Clinical Trials
San Diego, California
Unison Clinical Trials
Sherman Oaks, California
Skin Care Research
Boca Raton, Florida
Skin Research of South Florida
Miami, Florida
RM Medical Research
Miami Lakes, Florida
Advanced Clinical Research Institute
Tampa, Florida
Arlington Dermatology
Rolling Meadows, Illinois
Options Research Group
West Lafayette, Indiana
DS Research of Kentucky
Louisville, Kentucky
Oakland Hills Dermatology P.C
Auburn Hills, Michigan
Saginaw Bay Dermatology
Bay City, Michigan
Skin Cancer and Dermatology Institute
Reno, Nevada
Forest Hills Dermatology Group
Kew Gardens, New York
Rodgers Dermatology
Frisco, Texas
Dermatology Of Seattle
Bellevue, Washington
Oshawa Clinic Dermatology Trials
Oshawa, Ontario, Canada
Research Toronto
Toronto, Ontario, Canada
Innovaderm Research Inc
Montreal, Quebec, Canada
Centre de Recherche Saint-Louis
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.